In breast and prostate cancers, EZH2 over-expression is linked to aggressive tumor formation and poor prognosis [30,31] and in a subset of cancers, the EZH2 locus is amplified resulting in EZH2 over-expression [31,32]. Here, EZH2 is linked to prostate cancer.